Prostate cancer: Grade group 2 is associated with higher treatment rate

Key clinical point: In patients with prostate cancer undergoing active surveillance (AS), Gleason grade group (GG) 2 compared with GG1 at diagnosis was associated with a higher definitive treatment rate.

Major finding: There was no significant difference in the 5-year reclassification rates in patients with GG2 vs GG1 disease (30% vs 37%; P = .11). A higher proportion of patients with GG2 disease received treatment at 5 years (58% vs 34%; P < .001).

Study details: A prospective multicenter Canary PASS cohort study of 1,728 patients undergoing AS.

Disclosures: This work was supported by Canary Foundation and Institute for Prostate Cancer Research. The authors reported no conflict of interests.

Source: Malaret AJW et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002354.

Key clinical point: In patients with prostate cancer undergoing active surveillance (AS), Gleason grade group (GG) 2 compared with GG1 at diagnosis was associated with a higher definitive treatment rate.

Major finding: There was no significant difference in the 5-year reclassification rates in patients with GG2 vs GG1 disease (30% vs 37%; P = .11). A higher proportion of patients with GG2 disease received treatment at 5 years (58% vs 34%; P < .001).

Study details: A prospective multicenter Canary PASS cohort study of 1,728 patients undergoing AS.

Disclosures: This work was supported by Canary Foundation and Institute for Prostate Cancer Research. The authors reported no conflict of interests.

Source: Malaret AJW et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002354.

Key clinical point: In patients with prostate cancer undergoing active surveillance (AS), Gleason grade group (GG) 2 compared with GG1 at diagnosis was associated with a higher definitive treatment rate.

Major finding: There was no significant difference in the 5-year reclassification rates in patients with GG2 vs GG1 disease (30% vs 37%; P = .11). A higher proportion of patients with GG2 disease received treatment at 5 years (58% vs 34%; P < .001).

Study details: A prospective multicenter Canary PASS cohort study of 1,728 patients undergoing AS.

Disclosures: This work was supported by Canary Foundation and Institute for Prostate Cancer Research. The authors reported no conflict of interests.

Source: Malaret AJW et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002354.